```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a C7E3 valuable laboratory reagent extensively used in cardiovascular research . This antibody fragment specifically targets the glycoprotein IIb/IIIa binding site on platelets , blocking clot formation . Consequently , it's often investigated as a tool to explore the pathways underlying coagulation and to assess the efficacy of antithrombotic drugs . Availability is typically restricted to academic settings.
```
Abciximab Drug Research: Utilizing C7E3 Antibody and The 143653-53-6 Substance in Studies
Ongoing studies into abciximab, a GPIIb/IIIa, frequently utilizes the monoclonal antibody C7E3 and the substance identified as 143653-53-6. These materials are crucial for examining abciximab's mode of function, assessing its therapeutic effect in various clinical settings, and understanding potential predictors of therapeutic success. Further investigation leveraging these particular reagents is likely to yield valuable insights for optimizing therapeutic strategies related to cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Avenues with Abciximab 143653-53-6 using C7E3
Recent studies demonstrate that this antiplatelet agent (identified as 143653-53-6) presents significant research potential, particularly when paired with C7E3. Initial reports have that this association may boost therapeutic outcomes in various cardiovascular contexts. Further examination is directed on defining the specific mechanism of effect between the antiplatelet medication and C7E3, involving analysis of blood clot clumping and blood vessel safeguarding.
- Current investigation endeavors seek to maximize delivery protocols.
- Animal systems are are being employed to additional assess the theories.
- Clinical trials are essential to thoroughly evaluate therapeutic effectiveness.
```
Abciximab (C7E3) for Research: Specifications and Specifications (143653-53-6)
Researchers needing C7E3 for in vitro investigations should meticulously assess purity and defined specifications . The compound is typically supplied as a lyophilized powder and comprehensive analytical information including verification by mass spectrometry , biological activity assays, and bacterial endotoxin testing must be available. Verify the source’s documentation specifies acceptable values for impurities and meets established quality assurance guidelines.
High-Purity Abciximab Details & Stock
Acquiring laboratory-grade Abciximab, specifically referencing the molecule C7E3 and identified by the chemical number 143653-53-6, requires detailed consideration of its manufacturer. This glycoprotein is widely utilized in laboratory investigations , particularly those related to platelet aggregation and occlusion. Available sources offer this reagent in varying volumes, typically ranging from g to substantial bulk amounts . Please advise reviewing the report of testing to verify purity and suitability for your specific purpose. Additionally , confirm the expiration date before obtaining to maintain ideal effectiveness.
- Typical Purity: >95%
- Preservation Conditions: -20°C in suitable conditions
- Intended Purpose: Platelet Adhesion Suppression Studies